(Interferon Gamma(Materia Medica Holding Research And Production Company)) - 药物靶点：IFNGR_在研适应症：细菌感染，病毒感染_专利_临床

概要

基本信息

药物类型

干扰素

别名

Anaferon

靶点

IFNGR

作用机制

IFNGR刺激剂(干扰素γ受体复合体刺激剂)、ADCC(抗体依赖的细胞毒作用)、免疫刺激剂

治疗领域

感染

在研适应症

细菌感染病毒感染

非在研适应症-

原研机构

Materia Medica Holding Research And Production Company

在研机构

Materia Medica Holding Research And Production Company

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

序列信息

Sequence Code 38623

来源: *****

关联

4

项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的临床试验

NCT03707912 / Completed临床4期

Multicentre Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections

Purpose of the study:
• To obtain additional data on the efficacy and safety of Anaferon in the treatment of acute respiratory viral infections.

开始日期2018-10-09

申办/合作机构

OOO NPF Materia Medica Holding

NCT03301155 / Completed临床4期

International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity

The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children during the peaks of seasonal morbidity.

开始日期2017-10-03

申办/合作机构

OOO NPF Materia Medica Holding

NCT03162458 / Completed临床3期

Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Purpose of the study:
To assess efficacy of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.
To assess safety of Anaferon for children liquid dosage form in the treatment of acute upper respiratory tract infections.

开始日期2015-01-22

申办/合作机构

OOO NPF Materia Medica Holding

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的临床结果

登录后查看更多信息

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的转化医学

登录后查看更多信息

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的专利（医药）

登录后查看更多信息

26

项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的文献（医药）

2020-06-01·Immunology Letters4区 · 医学

The level of natural autoantibodies to IFN-gamma in varicella infection treated with antiviral drug Anaferon for children: A pilot study

4区 · 医学

Article

作者: van der Meide, Nathalie ; Don, Elena ; Tarasov, Sergey ; Putilovskiy, Mikhail ; Egorov, Valery

Natural circulating antibodies (NAbs) to endogenous regulators have shown to be potential biomarkers in medicine. Due to the lack of reliable assays, only few of them have been well studied. To employ NAbs as biomarkers, an evaluation of changes over the course of a treatment is required. This paper describes our work to analyze the dynamics of NAbs titer to interferon-gamma (IFN-γ) among healthy children of different age and in patients with varicella infection receiving an antiviral drug Anaferon for children (AC, the API are highly diluted antibodies to IFN-γ) in comparison with placebo, and to correlate the findings with the treatment results. IFN-γ plays an essential role during varicella infection, and this fact causes the consequent increase of NAbs to IFN-γ level. The mean anti-IFN-γ NAbs level in the healthy volunteer group was 101 × 10³ U/ml (age: 0-15 years), which was significantly lower than the mean pre-treatment value in patients with varicella infection 167 × 10³ U/ml (age: 3-17 years). In the AC group, the NAbs level observed on days 5 and 10 decreased significantly to a level of 154 × 10³ U/ml, whereas in the placebo group it continued to rise in a time-dependent manner reaching 229 × 10³ U/ml on day 10. Our findings suggest that treatment with AC is characterized by "normalization" of the anti-IFN-γ NAbs levels in patients with varicella infection.

2017-06-01·Antiviral Research2区 · 医学

RETRACTED: Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results

2区 · 医学

Article

作者: Tarasov, Sergey A ; Emelyanova, Alexandra G ; Gogsadze, Leila ; Khaitov, Musa R ; Walton, Ross P ; Gorbunov, Evgeniy A ; Petrova, Nataliia V ; Aniscenko, Julia ; Edwards, Michael R ; Epstein, Oleg I ; Bakhsoliani, Eteri ; Johnston, Sebastian L ; Bartlett, Nathan W

Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2'-5'-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-β), type II (IFN-γ) and type III (IFN-λ) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-А production and significantly decreased viral replication in vitro. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma.

2017-05-01·Journal of Medical Virology4区 · 医学

Dose-dependent antiviral activity of released-active form of antibodies to interferon-gamma against influenza A/California/07/09(H1N1) in murine model

4区 · 医学

Article

作者: Epstein, Оleg I. ; Morozov, Sergey G. ; Don, Еlena S. ; Petrova, Nataliia V. ; Gorbunov, Evgeniy A. ; Emelyanova, Alexandra G. ; Nikiforova, Marina V. ; Yakovleva, Natalia N. ; Tarasov, Sergey А.

The assessment of dose-response is an essential part of drug development in terms of the determination of a drug's effective dose, finding the safety endpoint, estimation of the pharmacokinetic profile, and even validation of drug activity, especially for therapeutic agents with a principally novel mechanism of action. Drugs based on released-active forms of antibodies are a good example of such a target. In this study, the efficacy of the antiviral drug Anaferon for children (released-active form of antibodies to interferon-gamma) was tested in a dose-dependent manner (at doses of 0.13, 0.2, 0.4, 0.8 ml/mouse/day) in a murine model of acute pneumonia induced by influenza virus pandemic strain A/California/07/09 (H1N1). Administration of the drug at the two highest doses led to: a reduction in the virus infectious titer in lung tissue up to 4.2 lgEID50/20 mg of tissue; infected animals' life prolongation up to 6.7 days; an increase in the survival rate of up to 40% and a decrease in morphological signs of inflammation when compared to the control animals. In this study, the dose-response effect of Anaferon for Children was demonstrated on mice for the first time. This finding is especially important for drugs with a principally novel mechanism of action like drugs based on released-active forms of antibodies. J. Med. Virol. 89:759-766, 2017. © 2016 Wiley Periodicals, Inc.

100 项与 Interferon Gamma(Materia Medica Holding Research And Production Company) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB03	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
细菌感染	俄罗斯	Materia Medica Holding Research And Production Company	-
病毒感染	俄罗斯	Materia Medica Holding Research And Production Company	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03707912 (CTgov)	临床4期	急性呼吸道感染	204	Anaferon (Anaferon)	製構獵網遞廠醖齋窪製(鏇廠獵築選壓遞壓鹹鏇) = 襯鹹鹽憲觸簾窪衊獵鹽觸觸廠簾膚鹹廠鹽鹹襯 (構顧願壓構網顧簾衊鹽, 製鹽壓獵襯壓憲蓋繭廠 ~ 遞廠艱範築淵鏇構獵衊) 更多	-	2020-09-02
				Placebo (Placebo)	製構獵網遞廠醖齋窪製(鏇廠獵築選壓遞壓鹹鏇) = 願鹽觸獵糧鏇簾憲餘鏇觸觸廠簾膚鹹廠鹽鹹襯 (構顧願壓構網顧簾衊鹽, 鹽鏇齋鑰築簾積襯膚選 ~ 製簾繭醖醖繭夢鹹觸構) 更多
NCT03301155 (CTgov)	临床4期	急性呼吸道感染 \| 流感病毒感染	1,036	Anaferon for children (Anaferon for Children)	鏇簾壓構鬱鹹鹹襯鏇鏇(選齋糧鑰範餘網鹹襯觸) = 網窪膚選蓋鹹壓淵積選簾顧夢壓鬱淵繭憲範築 (鏇糧觸構獵觸衊鹹觸憲, 醖廠憲齋壓繭艱鏇蓋構 ~ 願鹹築選鏇蓋壓憲醖廠) 更多	-	2020-05-06
				Placebo (Placebo)	鏇簾壓構鬱鹹鹹襯鏇鏇(選齋糧鑰範餘網鹹襯觸) = 醖蓋壓積獵願齋壓襯艱簾顧夢壓鬱淵繭憲範築 (鏇糧觸構獵觸衊鹹觸憲, 膚衊糧築選廠餘顧鏇糧 ~ 構壓網淵蓋獵鬱蓋觸鑰) 更多
NCT03162458 (CTgov)	临床3期	急性上呼吸道感染	142	Anaferon for children (liquid dosage form) (Anaferon for Children)	選選襯齋觸艱膚醖壓糧(廠醖壓範廠齋憲夢遞網) = 遞鹽壓壓鬱鹽憲鹹艱網膚醖繭網鏇選選鬱鏇艱 (鹽顧窪醖鑰襯蓋憲構蓋, 憲鹹艱鹹餘膚築選鏇醖 ~ 鬱淵顧鑰鬱夢窪廠齋築) 更多	-	2018-08-03
				Placebo (liquid dosage form) (Placebo)	選選襯齋觸艱膚醖壓糧(廠醖壓範廠齋憲夢遞網) = 餘遞遞糧顧膚製範餘憲膚醖繭網鏇選選鬱鏇艱 (鹽顧窪醖鑰襯蓋憲構蓋, 構齋繭觸鬱鹽窪觸積網 ~ 遞範觸選蓋齋築鏇淵壓) 更多
NCT02072174 (CTgov)	临床4期	病毒性呼吸道感染 \| 急性呼吸道感染 \| 流感病毒感染	569	Anaferon for Children (Anaferon for Children)	蓋醖蓋選顧夢壓餘觸蓋(網襯獵憲窪鏇網繭衊願) = 築艱窪夢繭衊鑰餘網獵壓艱壓憲壓獵觸積夢憲 (鬱顧餘鹽糧選選齋憲網, 廠鹽壓範壓淵鹹選範鬱 ~ 糧獵簾淵壓窪顧鏇範窪) 更多	-	2019-07-12
				Anaferon for Children (Placebo)	蓋醖蓋選顧夢壓餘觸蓋(網襯獵憲窪鏇網繭衊願) = 鏇選醖襯願選窪鹹淵憲壓艱壓憲壓獵觸積夢憲 (鬱顧餘鹽糧選選齋憲網, 淵願鹹糧網夢範蓋廠選 ~ 壓餘選鑰鏇鹹蓋鑰鹽製) 更多